
Otonomy (NASDAQ: OTIC)
Some price data may be temporarily unavailable.
Otonomy Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Otonomy Company Info
Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.
News & Analysis
Why H&R Block, Dycom Industries, and Otonomy Slumped Today
Despite a solid performance from the market, these stocks dropped. Find out why.
Here's Why the Market Is Eviscerating Otonomy Inc. Stock Today
Dismal trial results for steroid candidate Otividex in Meniere's disease patients blew a hole in the company's plans.
Valuation
Earnings Transcripts
Otonomy (OTIC) Q2 2022 Earnings Call Transcript
OTIC earnings call for the period ending June 30, 2022.
Otonomy (OTIC) Q1 2022 Earnings Call Transcript
OTIC earnings call for the period ending March 31, 2022.
Otonomy (OTIC) Q4 2021 Earnings Call Transcript
OTIC earnings call for the period ending December 31, 2021.
Otonomy (OTIC) Q4 2020 Earnings Call Transcript
OTIC earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.